Proprietary spray delivers micro doses of psilocybin or N-acetylcysteine for treatment of PTSD and traumatic brain injury Vancouver, British Columbia–(Newsfile Corp. – February 18, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“ Lobe” or the “Company“) announced today the completion and testing of the proof-of-concept prototype of its proprietary nasal mist device.


Previous articleMindMed Reaches Agreement to Acquire HealthMode, a Leading Machine Learning Digital Medicine Company
Next articleRed Light Holland Receives Receipt for Final Short-form Prospectus for Previously Announced $10 Million Bought Deal Public Offering